CEO Roby Zomer discusses Argent BioPharma’s future in pharmaceuticals
–News Direct– Argent BioPharma managing director and CEO Roby Zomer speaks to Proactive's Stephen Gunnion following the company's rebranding from MGC Pharmaceuticals, alongside a comprehensive restructuring. Zomer explained the shift marks a refined focus on the pharmaceutical sector, discarding previous activities not aligned with pure pharmaceutical processes. Zomer highlighted the companys advancement in drug discovery, particularly through a multidisciplinary approach and modern technologies such as nanotechnology and mRNA modulation. These innovations are targeted at addressing unmet medical needs. The company
Read more